Immune-mediated hemolytic anemia (IMHA) is a serious and potentially fatal disease that can occur in both dogs and cats. The disease often has an acute onset, making rapid recognition and timely treatment essential for a successful outcome.
The diagnosis and treatment of IMHA can, however, be very challenging. No single diagnostic test is completely reliable, and some patients do not respond as expected to standard therapy. IMHA also presents differently in dogs and cats. In general, the prognosis is poorer in dogs, where severe complications such as thromboembolism and SIRS (systemic inflammatory response syndrome) are seen more frequently than in cats.
In this short, focused webinar, we first review the physiology, diagnosis, and treatment of IMHA. We provide practical tools to help you reach a correct diagnosis, and we discuss how to approach persistent or difficult-to-treat cases in clinical practice.
The webinar also covers the important differences between dogs and cats, as well as the recently published ACVIM consensus guidelines on the diagnosis and treatment of IMHA in both species.
